TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9480180

Group type: EXPERIMENTAL
Intervention: Pharmacological protection
Number of subjects: 20
Study: 8494079

Group type: EXPERIMENTAL
Intervention: Imipramine treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine treatment after dosage increases or disulfiram
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3095641

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg intramuscular dose
Number of subjects: 122

Group type: COMPARATOR
Intervention: Kanamycin 75 mg intramuscular dose plus topical gentamicin for 7 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Kanamycin 75 mg intramuscular dose plus topical tetracycline for 7 days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Kanamycin 75 mg intramuscular dose
Number of subjects: 122
Study: 30200092

Group type: EXPERIMENTAL
Intervention: Thyroid tablet 0.4 mg/kg taken orally once a day for 4 days before surgery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 27348542

Group type: EXPERIMENTAL
Intervention: 0.1 mg triptoreline
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard luteal support with vaginal micronised progesterone
Number of subjects: 98
Study: 23992038

Group type: EXPERIMENTAL
Intervention: mHealth intervention (SMS text messages, e-mails, smartphone applications, Internet forums)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control (printed diet booklet)
Number of subjects: 51
Study: 22483419

Group type: EXPERIMENTAL
Intervention: Total dairy intake
Number of subjects: 33625

Group type: EXPERIMENTAL
Intervention: Fermented dairy
Number of subjects: 33625

Group type: EXPERIMENTAL
Intervention: Total dairy (among participants without hypertension)
Number of subjects: 33625

Group type: EXPERIMENTAL
Intervention: Low-fat dairy (among participants without hypertension)
Number of subjects: 33625

Group type: EXPERIMENTAL
Intervention: Total dairy and low-fat dairy (among hypertensive participants)
Number of subjects: 33625
Study: 21740277

Group type: EXPERIMENTAL
Intervention: Eyeliner adjunct to IPL
Number of subjects: 62

Group type: COMPARATOR
Intervention: Color-dye adjunct to IPL
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Eyeliner group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Color-dye group
Number of subjects: 62
Study: 18295626

Group type: EXPERIMENTAL
Intervention: Arc-RAD
Number of subjects: 30

Group type: COMPARATOR
Intervention: C-RAD
Number of subjects: 30
Study: 17027354

Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 25 mg mifepristone
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 12740742

Group type: EXPERIMENTAL
Intervention: Runners (increased training volume by 16%)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonathletes (sedentary controls)
Number of subjects: 17
Study: 11116697

Group type: EXPERIMENTAL
Intervention: Dynamic Strategy (DS)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tendency Oriented Perimetry (TOP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal Strategy (NS)
Number of subjects: 77
Study: 8627046

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (bacteriologic response in mice)
Number of subjects: 0
Study: 1351489

Group type: EXPERIMENTAL
Intervention: Salbutamol, 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol, 12 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2423337

Group type: EXPERIMENTAL
Intervention: beta-sitosteryl beta-D-glucoside (WA184) at a dose of 0.3 mg/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 53
Study: 29531924

Group type: EXPERIMENTAL
Intervention: PGB 75 mg daily
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PGB 75 mg daily and Met 500 mg daily for 3 months
Number of subjects: 71
Study: 27538513

Group type: EXPERIMENTAL
Intervention: Yogic breathing (YB) for 20 minutes (two exercises of 10 minutes each)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention Control (AC) - reading a text for 20 minutes
Number of subjects: 20
Study: 23644549

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg every 4 weeks
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg every 4 weeks
Number of subjects: 356

Group type: COMPARATOR
Intervention: placebo crossover
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Patients without baseline syndesmophytes
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Patients with baseline CRP levels <1.5 mg/dl
Number of subjects: 356
Study: 22575398

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Emergency endoscopic therapy (EST)
Number of subjects: 211
Study: 20157661

Group type: EXPERIMENTAL
Intervention: Light curing after inlay insertion
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dual curing adhesive and luting composite (LC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Separate light polymerization of XP Bond
Number of subjects: 48
Study: 18381571

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332
Study: 16723055

Group type: EXPERIMENTAL
Intervention: 20 mg morphine sulphate orally every 4 h for 24 h
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulphate orally every 4 h for 24 h
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg morphine sulphate orally every 4 h for 16 h (pharmacokinetic study)
Number of subjects: 60
Study: 12855090

Group type: EXPERIMENTAL
Intervention: Experiential-Cognitive Therapy (ECT) - 8 sessions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 12 sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 12
Study: 10777986

Group type: EXPERIMENTAL
Intervention: Very Low Density Lipoprotein (VLDL) and High Density Lipoprotein (HDL) levels
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Mathematical model of population incidence of DM
Number of subjects: 600
Study: 9208626

Group type: EXPERIMENTAL
Intervention: Methimazole (40 mg/d, tapered to 20 mg/d after two weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methimazole combined with Dexamethasone (Dex, 6 mg/d, reduced to 4.5 mg/d on the 5th day and to 2.25 mg/d two weeks after treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (20 normals)
Number of subjects: 32
Study: 1597229

Group type: EXPERIMENTAL
Intervention: Diltiazem (90 mg t.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gallopamil (50 mg t.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6397331

Group type: EXPERIMENTAL
Intervention: Flunisolide (2 sprays to each nostril twice daily for 7 weeks)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (2 sprays to each nostril twice daily for 7 weeks)
Number of subjects: 69
Study: 31531996

Group type: EXPERIMENTAL
Intervention: Creatine Group (CG) - received creatine plus maltodextrin, 1st week: 20 g/day of creatine plus 20 g/day of maltodextrin and 2nd-4th weeks: 5 g/day of creatine plus 5 g/day of maltodextrin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo Group (PG) - received maltodextrin, 1st week: 40 g/day and 2nd-4th weeks: 10 g/day
Number of subjects: 30
Study: 30566027

Group type: EXPERIMENTAL
Intervention: Primary Progressive MS (PPMS) patients
Number of subjects: 1889

Group type: COMPARATOR
Intervention: SELs
Number of subjects: 1889
Study: 28122280

Group type: EXPERIMENTAL
Intervention: Chan-Chuang qigong (21-day programme)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 25479146

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (nerve blocks and incision infiltration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (control group)
Number of subjects: 60
Study: 24284609

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation containing B-vitamins
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Homocysteine (HCy) levels
Number of subjects: 138
Study: 20808114

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) program, including psychoeducation and cognitive training, delivered in a group format over a 10-week period, each component lasting 1 hour.
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control group (not receiving the intervention)
Number of subjects: 41
Study: 17962204

Group type: EXPERIMENTAL
Intervention: CapOx (capecitabine 1000 mg/m² twice daily on days 1‐14 plus oxaliplatin 130 mg/m² on day 1)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CapGem (capecitabine 825 mg/m² twice daily on days 1‐14 plus gemcitabine 1000 mg/m² on days 1 and 8)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: mGemOx (gemcitabine 1000 mg/m² on days 1 and 8 plus oxaliplatin 130 mg/m² on day 8)
Number of subjects: 190
Study: 16816537

Group type: EXPERIMENTAL
Intervention: C-reactive protein as a prognostic marker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procalcitonin alone or in combination with interleukin-6
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotic prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical and/or clinical predictive systems
Number of subjects: 0
Study: 12942055

Group type: EXPERIMENTAL
Intervention: Plastic dual-arch tray
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metal dual-arch tray
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Complete-arch custom tray
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Overall comfort ranking
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of die accuracy
Number of subjects: 8
Study: 9377610

Group type: EXPERIMENTAL
Intervention: Naprelan 1000 mg QD
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Nabumetone 1500 mg QD
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 1396427

Group type: EXPERIMENTAL
Intervention: Centromedian thalamic stimulation (on)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Centromedian thalamic stimulation (off)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Open-label follow-up stimulation (24 h/day)
Number of subjects: 7
Study: 3914623

Group type: EXPERIMENTAL
Intervention: 3g of ascorbic acid per day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 28460137

Group type: EXPERIMENTAL
Intervention: Higher adherence to the Mediterranean diet (measured by the Literature-based Adherence Score to the Mediterranean Diet - LAMD)
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3012
Study: 28221010

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (cTnT) level on admission
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: cTnT level combined with Pneumonia Severity Index (PSI) classification
Number of subjects: 295
Study: 26245894

Group type: EXPERIMENTAL
Intervention: Intra-tympanic dexamethasone
Number of subjects: 30
Study: 24228533

Group type: EXPERIMENTAL
Intervention: Integrated treatment of traditional Chinese medicine and Western medicine (TCM-WM)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Western medicine treatment
Number of subjects: 164
Study: 21128114

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 606

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 606
Study: 18498883

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine (AE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine (LE)
Number of subjects: 40
Study: 16553541

Group type: EXPERIMENTAL
Intervention: Fluoxetine 40-60 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 29
Study: 14977438

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (90 mg total isoflavones/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10640116

Group type: EXPERIMENTAL
Intervention: Joint protection (JP) education programme
Number of subjects: 35
Study: 8961990

Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy (40 Gy in 20 fractions of 2 Gy over 4 weeks)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Surgery followed by radiotherapy
Number of subjects: 469
Study: 1902418

Group type: EXPERIMENTAL
Intervention: Mitomycin C or Adriamycin, administered endovesically
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (original series)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extravesical recurrences
Number of subjects: 40
Study: 6124859

Group type: EXPERIMENTAL
Intervention: 200 mg bupropion p.o.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31273507

Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variables (amplitude, r24, I < O)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variables (amplitude, r24, IS, IV)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Circadian activity rhythm variable (IV)
Number of subjects: 33
Study: 31856964

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infarct-related artery revascularization only
Number of subjects: 0
Study: 29356608

Group type: EXPERIMENTAL
Intervention: CHOP-RIT (CHOP followed by consolidation with iodine-133-Tositumomab radioimmunotherapy)
Number of subjects: 531

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: CHOP-RIT
Number of subjects: 531

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 531
Study: 26757989

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) point-of-care testing
Number of subjects: 297
Study: 24641985

Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet laser (fluence of 5 J/cm(2), rate of 6 Hz)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:yttrium-aluminum-garnet laser
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1064-nm neodymium:ytrium-aluminum-garnet laser
Number of subjects: 27
Study: 21248779

Group type: EXPERIMENTAL
Intervention: Rapid cuff inflation (<1 s)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Slow cuff inflation (10 s)
Number of subjects: 33
Study: 20633873

Group type: EXPERIMENTAL
Intervention: Mindful Breathing (MB)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Loving-Kindness Meditation (LKM)
Number of subjects: 190
Study: 17516829

Group type: EXPERIMENTAL
Intervention: Low-dose recombinant IGF-I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15738542

Group type: EXPERIMENTAL
Intervention: docetaxel (70 mg/m2 on day 2 or 35 mg/m2 on days 2 and 9 of each 21‐day cycle) and estramustine (280 mg p.o. tid on days 1 through 5 and 8 through 12) plus prednisone (10 mg daily)
Number of subjects: 130

Group type: COMPARATOR
Intervention: mitoxantrone (12 mg/m2 every 3 weeks) plus prednisone (10 mg daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: docetaxel arms (DEP)
Number of subjects: 130
Study: 11943004

Group type: EXPERIMENTAL
Intervention: Dual-wave insulin administration (70% as a bolus and 30% as a square-wave over 2 h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Square-wave insulin administration (over 2 h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Single bolus insulin administration
Number of subjects: 9

Group type: COMPARATOR
Intervention: Double bolus insulin administration (two separate boluses of one-half the same total dose)
Number of subjects: 9
Study: 10768034

Group type: EXPERIMENTAL
Intervention: Vertical columns arrangement of letters (constant horizontal distance)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Original Bailey-Lovie chart
Number of subjects: 112
Study: 7574855

Group type: EXPERIMENTAL
Intervention: Clear apple juice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cloudy apple juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Extra clear fluids (excluding fruit juices)
Number of subjects: 12
Study: 2200384

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Verapamil SR
Number of subjects: 306

Group type: COMPARATOR
Intervention: Control (Stable or forced-dose titration sequence)
Number of subjects: 306
Study: 7345158

Group type: EXPERIMENTAL
Intervention: Men's group treatment of erectile dysfunction with communication and dating skills training; 10 sessions over 6 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Waiting control period
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Men's group treatment of erectile dysfunction
Number of subjects: 11
Study: 31106728

Group type: EXPERIMENTAL
Intervention: DISCOVER one-day CBT workshop
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 31221944

Group type: EXPERIMENTAL
Intervention: 500 mg BioCell Collagen supplement taken twice daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 28702758

Group type: EXPERIMENTAL
Intervention: Text message intervention (112 messages)
Number of subjects: 411
Study: 26369333

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) and static stretching (LLLT+Stretch)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) placebo and static stretching (LLLTPLACEBO+Stretch)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Static stretching alone
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) alone
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (booklet)
Number of subjects: 145
Study: 24158199

Group type: EXPERIMENTAL
Intervention: BNP of 500 pg/mL or greater
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RVEDVI of 140 mL/m or greater
Number of subjects: 81
Study: 21190036

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study: 19640922

Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg daily for 4 weeks annually)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 17680183

Group type: EXPERIMENTAL
Intervention: 3 : 1 mixture of Lipuro and FA (Lipuro-FA)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3 : 1 mixture of Dipri and FA (Dipri-FA)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Plain Lipuro
Number of subjects: 300

Group type: COMPARATOR
Intervention: Plain Dipri
Number of subjects: 300
Study: 12616435

Group type: EXPERIMENTAL
Intervention: Medial-to-lateral (M) group
Number of subjects: 67

Group type: COMPARATOR
Intervention: Lateral-to-medial (L) group
Number of subjects: 67
Study: 10979060

Group type: EXPERIMENTAL
Intervention: Montelukast plus Loratadine (10 mg Montelukast + 20 mg Loratadine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Montelukast alone (10 mg)
Number of subjects: 0
Study: 8804377

Group type: EXPERIMENTAL
Intervention: Liver transplantation, resection, or alcohol injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for hepatocellular carcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New imaging techniques (ultrasonographic angiography with CO2 microbubbles, color Doppler ultrasound)
Number of subjects: 0
Study: 1428573

Group type: EXPERIMENTAL
Intervention: 5 Fluoro‐Uracil (5FU) - 10 injections
Number of subjects: 25

Group type: COMPARATOR
Intervention: Daunorubicin - 1 subconjunctival preoperative injection
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 Fluoro‐Uracil (5FU)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Daunorubicin
Number of subjects: 25
Study: 6428278

Group type: EXPERIMENTAL
Intervention: Cromolyn
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3549476

Group type: EXPERIMENTAL
Intervention: Radiotherapy plus intravenous Corynebacterium parvum (C. parvum)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: C. parvum therapy
Number of subjects: 283
Study: 30197273

Group type: EXPERIMENTAL
Intervention: 4 g OM-3CA
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 25743238

Group type: EXPERIMENTAL
Intervention: Oxygen-ozone (O2-O3) discolysis with steroid and anesthetic
Number of subjects: 154

Group type: COMPARATOR
Intervention: Steroid and anesthetic (Control Group)
Number of subjects: 154
Study: 23041591

Group type: EXPERIMENTAL
Intervention: Cetuximab maintenance therapy following definitive RT with concomitant cetuximab
Number of subjects: 91

Group type: COMPARATOR
Intervention: Concomitant cetuximab + RT (69.9 Gy) without maintenance
Number of subjects: 91
Study: 20630163

Group type: EXPERIMENTAL
Intervention: Intervention group (Lunch Is In The Bag program)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 132
Study: 17851252

Group type: EXPERIMENTAL
Intervention: Coital incontinence group
Number of subjects: 180
Study: 16369474

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15314387

Group type: EXPERIMENTAL
Intervention: Relaxing music (20 minutes once a day for 3 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (20 minutes of rest)
Number of subjects: 40